Association of treatment-achieved HbA

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Disease Research
• Ophthalmology and Vision Science

Background:

• Glycemic control, measured by HbA1c, is crucial for managing diabetes complications.
• Different diabetes treatment modalities may influence the risk of cardiovascular and ocular diseases differently.

Purpose of the Study:

• To investigate the association between HbA1c levels achieved with various diabetes treatments and the incidence of coronary artery disease (CAD) and severe diabetic eye disease.
• To compare these associations across different treatment groups.

Main Methods:

• Analysis of a nationwide claims database of 14,633 Japanese diabetes patients.
• Cox's regression analysis was used to examine risks over a 5.1-year follow-up period.
• Patients were categorized into treatment groups: diet only, insulin, sulfonylurea (SU) alone, SU with glinides, and other antihyperglycemic agents.

Main Results:

• A significant linear trend between HbA1c levels and CAD events was observed in the diet-only group.
• CAD risks were higher in insulin and SU groups with HbA1c ≤7.0% and >8.0% compared to the diet-only group with HbA1c ≤7.0%.
• A linear association between achieved HbA1c and severe diabetic eye disease risk was found across all treatment modalities, with no significant differences in risk between HbA1c ≤7.0% and 7.1-8.0% groups for SU, SU with glinides, or insulin treatments.

Conclusions:

• The relationship between treatment-achieved HbA1c and the incidence of CAD and severe diabetic eye disease varies depending on the specific diabetes treatment used.
• These findings, derived from a large-scale real-world database, underscore the importance of considering treatment modality when assessing glycemic control targets.
• Further research is warranted to confirm these results and elucidate the underlying mechanisms driving these differential associations.